Telix Pharmaceuticals (TLX) Long-Term Investments (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Long-Term Investments data on file, last reported at $37.1 million in Q4 2025.

• In Q4 2025, Long-Term Investments rose 1.12% year-over-year to $37.1 million; the TTM figure through Dec 2025 stood at $37.1 million (up 1.12% YoY), while the FY2025 annual figure was $37.1 million, up 6.76% from the prior year.
• Long-Term Investments advanced to $37.1 million in Q4 2025, from $36.7 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $37.1 million in Q4 2025 and bottomed at $8.0 million in Q4 2023.
• A 3-year average of $27.3 million and a median of $36.7 million in 2024 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2024 — Long-Term Investments jumped 359.61% — and 2025, when it rose 1.12%.
• Year by year, Long-Term Investments stood at $8.0 million in 2023, then jumped by 359.61% to $36.7 million in 2024, then grew by 1.12% to $37.1 million in 2025.
• The last three Long-Term Investments figures came in at $37.1 million (Q4 2025), $36.7 million (Q4 2024), and $8.0 million (Q4 2023), per Business Quant data.

Peer Comparison